Lampalizumab Keeps Intraocular Pressure Steady

Monthly intravitreous injections of 0.1 mL of lampalizumab over 1 year were associated with a low risk for adverse events associated with intraocular pressure in patients with geographic atrophy.
Medscape Medical News